Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Next Previous
Trial Profile

A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rozanolixizumab (Primary)
  • Indications Myasthenia gravis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors UCB Biopharma

Most Recent Events

  • 11 May 2023 Results of post hoc analysis assessing the newly developed MG Symptoms Patient-Reported Outcome (PRO) instrument complements the available measures of MG severity published in the Neurology and Therapy
  • 20 Nov 2020 Results published in the Neurology.
  • 18 Oct 2018 According to a UCB media release, full data from this study will be presented at a medical congress in the near future and submitted for publication in a peer-reviewed journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top